Skip to main content
Top

Open Access 03-02-2025 | Hydroxychloroquine | Review Article

Safety of Hydroxychloroquine: What a Dermatologist Should Know

Authors: Luca Rapparini, Stephano Cedirian, Michelangelo La Placa, Bianca Maria Piraccini, Emanuel Raschi, Michela Starace

Published in: American Journal of Clinical Dermatology

Login to get access

Abstract

The unique immunomodulatory properties of hydroxychloroquine (HCQ) have attracted considerable interest beyond its use for malaria and rheumatological diseases, including a variety of dermatological conditions. Over recent years, especially after the coronavirus disease 2019 (COVID-19) pandemic, the prescription of HCQ has also significantly expanded, sometimes inappropriately, thus posing additional challenges on its optimal use, due to emerging safety issues. In this review, we provide dermatologists with the latest advancements on selected clinically relevant toxicities, namely retinopathy, pro-arrhythmia, cutaneous reactions, and neuropsychiatric effects. It is hoped this update can assist dermatologists to identify high-risk patients for tailored monitoring, screening, and risk minimization strategies, thus supporting safer HCQ prescribing.
Literature
5.
go back to reference Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293–305.PubMedCrossRef Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293–305.PubMedCrossRef
6.
go back to reference Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.PubMedCrossRef Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.PubMedCrossRef
7.
go back to reference Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447–59.PubMedPubMedCentralCrossRef Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447–59.PubMedPubMedCentralCrossRef
8.
go back to reference Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–9.PubMedCrossRef Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–9.PubMedCrossRef
9.
go back to reference Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology. 2021;60(5):2317–26.PubMedCrossRef Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology. 2021;60(5):2317–26.PubMedCrossRef
10.
go back to reference Chambers CD, Johnson DL, Xu R, Luo Y, Felix R, Fine M, et al. Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study. Arthritis Rheumatol. 2022;74(4):711–24.PubMedCrossRef Chambers CD, Johnson DL, Xu R, Luo Y, Felix R, Fine M, et al. Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study. Arthritis Rheumatol. 2022;74(4):711–24.PubMedCrossRef
11.
go back to reference Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290.e1-290.e22.PubMedCrossRef Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290.e1-290.e22.PubMedCrossRef
12.
go back to reference Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet Rheumatology. 2023;5(9):e501–6.PubMedCrossRef Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet Rheumatology. 2023;5(9):e501–6.PubMedCrossRef
13.
go back to reference Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine. Rheumatology. 2024;63(2):e37–8.PubMedCrossRef Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine. Rheumatology. 2024;63(2):e37–8.PubMedCrossRef
14.
go back to reference Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis Rheum. 2002;47(3):285–90.PubMedCrossRef Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis Rheum. 2002;47(3):285–90.PubMedCrossRef
15.
go back to reference Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.PubMedPubMedCentralCrossRef Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.PubMedPubMedCentralCrossRef
16.
go back to reference Lenfant T, Costedoat-Chalumeau N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol. 2023;19(1):6–7.PubMedCrossRef Lenfant T, Costedoat-Chalumeau N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol. 2023;19(1):6–7.PubMedCrossRef
17.
go back to reference Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81.PubMedCrossRef Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81.PubMedCrossRef
18.
go back to reference Englert KA, Dyduch G, Kłosowicz A, Spałkowska M, Jaworek AK, Migacz-Gruszka K, et al. Cutaneous toll-like receptor 9 pre-defines hydroxychloroquine dosage in patients with both discoid and subacute lupus erythematosus. Medicina. 2023;59(11):2022.PubMedPubMedCentralCrossRef Englert KA, Dyduch G, Kłosowicz A, Spałkowska M, Jaworek AK, Migacz-Gruszka K, et al. Cutaneous toll-like receptor 9 pre-defines hydroxychloroquine dosage in patients with both discoid and subacute lupus erythematosus. Medicina. 2023;59(11):2022.PubMedPubMedCentralCrossRef
19.
go back to reference Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–14.PubMedPubMedCentralCrossRef Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–14.PubMedPubMedCentralCrossRef
20.
go back to reference Tripp JM, Maibach HI. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Am J Clin Dermatol. 2006;7(3):171–5.PubMedCrossRef Tripp JM, Maibach HI. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Am J Clin Dermatol. 2006;7(3):171–5.PubMedCrossRef
21.
go back to reference Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, et al. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: a retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2022;87(1):203–6.PubMedCrossRef Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, et al. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: a retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2022;87(1):203–6.PubMedCrossRef
22.
go back to reference Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. Acad Dermatol Venereol. 2019;33(10):1847–62.CrossRef Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. Acad Dermatol Venereol. 2019;33(10):1847–62.CrossRef
23.
go back to reference Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11–22.PubMedCrossRef Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11–22.PubMedCrossRef
24.
go back to reference Xie Y, Xu H, Li C, Wang Y, Lu R, Hua H, et al. Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis. 2024;30(5):3126–35.PubMedCrossRef Xie Y, Xu H, Li C, Wang Y, Lu R, Hua H, et al. Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis. 2024;30(5):3126–35.PubMedCrossRef
25.
go back to reference Starace M, Brandi N, Alessandrini A, Bruni F, Piraccini BM. Frontal fibrosing alopecia: a case series of 65 patients seen in a single Italian centre. Acad Dermatol Venereol. 2019;33(2):433–8.CrossRef Starace M, Brandi N, Alessandrini A, Bruni F, Piraccini BM. Frontal fibrosing alopecia: a case series of 65 patients seen in a single Italian centre. Acad Dermatol Venereol. 2019;33(2):433–8.CrossRef
26.
go back to reference Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019;20(3):379–90.PubMedCrossRef Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019;20(3):379–90.PubMedCrossRef
27.
go back to reference Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387–92.PubMedCrossRef Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387–92.PubMedCrossRef
28.
go back to reference Starace M, Cedirian S, Rapparini L, Quadrelli F, Pampaloni F, Bruni F, et al. Enhanced insights into frontal fibrosing alopecia: advancements in pathogenesis understanding and management strategies. Dermatol Ther (Heidelb). 2024;14(6):1457–77.PubMedPubMedCentralCrossRef Starace M, Cedirian S, Rapparini L, Quadrelli F, Pampaloni F, Bruni F, et al. Enhanced insights into frontal fibrosing alopecia: advancements in pathogenesis understanding and management strategies. Dermatol Ther (Heidelb). 2024;14(6):1457–77.PubMedPubMedCentralCrossRef
29.
go back to reference Nic Dhonncha E, Foley CC, Markham T. The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review. Dermatol Ther. 2017;30(3): e12463.CrossRef Nic Dhonncha E, Foley CC, Markham T. The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review. Dermatol Ther. 2017;30(3): e12463.CrossRef
30.
go back to reference Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–96.PubMedCrossRef Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–96.PubMedCrossRef
31.
go back to reference Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53.PubMedCrossRef Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53.PubMedCrossRef
32.
33.
go back to reference Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10(12):1402–9.PubMedPubMedCentralCrossRef Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10(12):1402–9.PubMedPubMedCentralCrossRef
34.
go back to reference Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117–34.PubMedCrossRef Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117–34.PubMedCrossRef
35.
go back to reference Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–94.PubMedCrossRef Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–94.PubMedCrossRef
36.
go back to reference Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321–6.PubMedCrossRef Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321–6.PubMedCrossRef
37.
go back to reference Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775–84.CrossRef Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775–84.CrossRef
38.
go back to reference Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.PubMedCrossRef Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.PubMedCrossRef
39.
go back to reference Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453.PubMedCrossRef Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453.PubMedCrossRef
40.
go back to reference Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294–304.PubMed Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294–304.PubMed
41.
go back to reference Lang GK. Ophthalmology: a short textbook. Stuttgart New York: Thieme; 2007. 586 p. (Thieme flexibook). Lang GK. Ophthalmology: a short textbook. Stuttgart New York: Thieme; 2007. 586 p. (Thieme flexibook).
42.
go back to reference Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122(6):1252–6.PubMedCrossRef Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122(6):1252–6.PubMedCrossRef
43.
go back to reference Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1):25–34.PubMedCrossRef Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1):25–34.PubMedCrossRef
44.
go back to reference Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis & Rheumatology. 2021;73(6):908–11.CrossRef Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis & Rheumatology. 2021;73(6):908–11.CrossRef
45.
go back to reference Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis & Rheumatology. 2016;68(1):184–90.CrossRef Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis & Rheumatology. 2016;68(1):184–90.CrossRef
46.
go back to reference Jorge AM, Melles RB, Marmor MF, Zhou B, Zhang Y, Choi HK. Risk factors for hydroxychloroquine retinopathy and its subtypes. JAMA Netw Open. 2024;7(5): e2410677.PubMedPubMedCentralCrossRef Jorge AM, Melles RB, Marmor MF, Zhou B, Zhang Y, Choi HK. Risk factors for hydroxychloroquine retinopathy and its subtypes. JAMA Netw Open. 2024;7(5): e2410677.PubMedPubMedCentralCrossRef
47.
go back to reference Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8):3531–8.PubMedCrossRef Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8):3531–8.PubMedCrossRef
48.
go back to reference Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109(7):1377–82.PubMedCrossRef Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109(7):1377–82.PubMedCrossRef
49.
go back to reference Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. Collaboration for the management of hydroxychloroquine. Ophthalmology. 2021;128(7):1115–6.PubMedCrossRef Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. Collaboration for the management of hydroxychloroquine. Ophthalmology. 2021;128(7):1115–6.PubMedCrossRef
50.
go back to reference Fett N, Werth VP. A Multidisciplinary collaborative approach to retinal toxic effects screening for dermatology patients taking antimalarials. JAMA Dermatol. 2021;157(9):1112.PubMedCrossRef Fett N, Werth VP. A Multidisciplinary collaborative approach to retinal toxic effects screening for dermatology patients taking antimalarials. JAMA Dermatol. 2021;157(9):1112.PubMedCrossRef
52.
go back to reference Salu P, Uvijls A, Van Den Brande P, Leroy BP. Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. Doc Ophthalmol. 2010;120(3):251–64.PubMedCrossRef Salu P, Uvijls A, Van Den Brande P, Leroy BP. Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. Doc Ophthalmol. 2010;120(3):251–64.PubMedCrossRef
53.
54.
go back to reference Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62(3):286–301.PubMedCrossRef Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62(3):286–301.PubMedCrossRef
55.
go back to reference Rubin ML, Thomas WC. Diplopia and loss of accommodation due to chloroquine. Arthritis Rheum. 1970;13(1):75–82.PubMedCrossRef Rubin ML, Thomas WC. Diplopia and loss of accommodation due to chloroquine. Arthritis Rheum. 1970;13(1):75–82.PubMedCrossRef
56.
go back to reference Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639–50.PubMedCrossRef Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639–50.PubMedCrossRef
57.
go back to reference Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A, et al. The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia. Curr Heart Fail Rep. 2020;17(6):365–83.PubMedPubMedCentralCrossRef Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A, et al. The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia. Curr Heart Fail Rep. 2020;17(6):365–83.PubMedPubMedCentralCrossRef
58.
go back to reference Wang X, Feng Y, Liu S, Liu J, Pan S, Wei L, et al. Hydroxychloroquine attenuates hERG channel by promoting the membrane channel degradation: computational simulation and experimental evidence for QT-interval prolongation with hydroxychloroquine treatment. Cardiology. 2023;148(4):310–23.PubMedCrossRef Wang X, Feng Y, Liu S, Liu J, Pan S, Wei L, et al. Hydroxychloroquine attenuates hERG channel by promoting the membrane channel degradation: computational simulation and experimental evidence for QT-interval prolongation with hydroxychloroquine treatment. Cardiology. 2023;148(4):310–23.PubMedCrossRef
59.
go back to reference Yu R, Li P. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021;30(458):152822.CrossRef Yu R, Li P. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021;30(458):152822.CrossRef
60.
go back to reference Ballet V, Bohme GA, Brohan E, Boukaiba R, Chambard JM, Angouillant-Boniface O, et al. In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. Eur J Pharmacol. 2022;15(915): 174670.CrossRef Ballet V, Bohme GA, Brohan E, Boukaiba R, Chambard JM, Angouillant-Boniface O, et al. In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. Eur J Pharmacol. 2022;15(915): 174670.CrossRef
61.
go back to reference Thomet U, Amuzescu B, Knott T, Mann SA, Mubagwa K, Radu BM. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. Eur J Pharmacol. 2021;15(913): 174632.CrossRef Thomet U, Amuzescu B, Knott T, Mann SA, Mubagwa K, Radu BM. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. Eur J Pharmacol. 2021;15(913): 174632.CrossRef
62.
go back to reference Szendrey M, Guo J, Li W, Yang T, Zhang S. COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels. J Pharmacol Exp Ther. 2021;377(2):265–72.PubMedCrossRef Szendrey M, Guo J, Li W, Yang T, Zhang S. COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels. J Pharmacol Exp Ther. 2021;377(2):265–72.PubMedCrossRef
63.
go back to reference Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, et al. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Intern Med J. 2023;53(3):311–7.PubMedCrossRef Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, et al. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Intern Med J. 2023;53(3):311–7.PubMedCrossRef
64.
go back to reference Saint-Gerons DM, Tabarés-Seisdedos R. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol. 2021;77(10):1513–21.PubMedPubMedCentralCrossRef Saint-Gerons DM, Tabarés-Seisdedos R. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol. 2021;77(10):1513–21.PubMedPubMedCentralCrossRef
65.
go back to reference Goldman A, Bomze D, Dankner R, Hod H, Meirson T, Boursi B, et al. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: a comprehensive pharmacovigilance analysis of pre-COVID-19 reports. Br J Clin Pharmacol. 2021;87(3):1432–42.PubMedCrossRef Goldman A, Bomze D, Dankner R, Hod H, Meirson T, Boursi B, et al. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: a comprehensive pharmacovigilance analysis of pre-COVID-19 reports. Br J Clin Pharmacol. 2021;87(3):1432–42.PubMedCrossRef
66.
go back to reference Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021;17(2):483–6.PubMedCrossRef Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021;17(2):483–6.PubMedCrossRef
67.
go back to reference Nishtala PS, Gill S, Chyou TY. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. Pharmacoepidemiol Drug Saf. 2020;29(12):1689–95.PubMedCrossRef Nishtala PS, Gill S, Chyou TY. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. Pharmacoepidemiol Drug Saf. 2020;29(12):1689–95.PubMedCrossRef
68.
go back to reference Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database. Circulation. 2020;142(3):303–5.PubMedPubMedCentralCrossRef Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database. Circulation. 2020;142(3):303–5.PubMedPubMedCentralCrossRef
69.
go back to reference Ezemma O, Devjani S, Jothishankar B, Kelley KJ, Senna MM. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023;62(9):e473–4.PubMedCrossRef Ezemma O, Devjani S, Jothishankar B, Kelley KJ, Senna MM. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023;62(9):e473–4.PubMedCrossRef
70.
go back to reference Obijiofor CE, Sikora M, Liu L, Stern MJ, Hena KM, Mazori DR, et al. Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: a multicenter retrospective study. J Am Acad Dermatol. 2024;S0190–9622(24):00911–3. Obijiofor CE, Sikora M, Liu L, Stern MJ, Hena KM, Mazori DR, et al. Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: a multicenter retrospective study. J Am Acad Dermatol. 2024;S0190–9622(24):00911–3.
71.
go back to reference Collins M, Ali S, Wiss IP, Senna MM. Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia. J Am Acad Dermatol. 2023;88(2):434–5.PubMedCrossRef Collins M, Ali S, Wiss IP, Senna MM. Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia. J Am Acad Dermatol. 2023;88(2):434–5.PubMedCrossRef
72.
go back to reference Desmarais J, Rosenbaum JT, Costenbader KH, Ginzler EM, Fett N, Goodman S, et al. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021;73(12):2151–60.PubMedCrossRef Desmarais J, Rosenbaum JT, Costenbader KH, Ginzler EM, Fett N, Goodman S, et al. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021;73(12):2151–60.PubMedCrossRef
73.
go back to reference Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–87.PubMedPubMedCentralCrossRef Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–87.PubMedPubMedCentralCrossRef
74.
go back to reference Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381–90.PubMedPubMedCentralCrossRef Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381–90.PubMedPubMedCentralCrossRef
75.
go back to reference Tétu P, Hamelin A, Lebrun-Vignes B, Soria A, Barbaud A, Francès C, et al. Prévalence des effets indésirables de l’hydroxychloroquine (Plaquenil ® ) dans une population dermatologique : étude rétrospective sur 102 patients. Ann Dermatol Venereol. 2018;145(6–7):395–404.PubMedCrossRef Tétu P, Hamelin A, Lebrun-Vignes B, Soria A, Barbaud A, Francès C, et al. Prévalence des effets indésirables de l’hydroxychloroquine (Plaquenil ® ) dans une population dermatologique : étude rétrospective sur 102 patients. Ann Dermatol Venereol. 2018;145(6–7):395–404.PubMedCrossRef
76.
go back to reference Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021;39(5):1099–107.PubMedCrossRef Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021;39(5):1099–107.PubMedCrossRef
77.
go back to reference Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563–78.PubMedCrossRef Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563–78.PubMedCrossRef
78.
go back to reference Hosokawa Y, Oiwa H. Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese Municipal Hospital. Intern Med. 2020;59(20):2485–90.PubMedPubMedCentralCrossRef Hosokawa Y, Oiwa H. Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese Municipal Hospital. Intern Med. 2020;59(20):2485–90.PubMedPubMedCentralCrossRef
79.
go back to reference Zamani B, Hasan-Abad AM, Rafizadeh SM, Akbari H, Motedayyen H. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous. J Immunoassay Immunochem. 2024;45(3):178–88.PubMedCrossRef Zamani B, Hasan-Abad AM, Rafizadeh SM, Akbari H, Motedayyen H. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous. J Immunoassay Immunochem. 2024;45(3):178–88.PubMedCrossRef
80.
go back to reference Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: what dermatologists should know. J Dermatol. 2024;51(7):895–903.PubMedCrossRef Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: what dermatologists should know. J Dermatol. 2024;51(7):895–903.PubMedCrossRef
81.
go back to reference Kishi C, Motegi S, Yasuda M, Ishikawa O. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients. J Dermatol. 2018;45(8):1020–2.PubMedCrossRef Kishi C, Motegi S, Yasuda M, Ishikawa O. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients. J Dermatol. 2018;45(8):1020–2.PubMedCrossRef
82.
go back to reference Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol. 1999;79(4):333–333.PubMedCrossRef Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol. 1999;79(4):333–333.PubMedCrossRef
83.
go back to reference Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol. 2004;50(4):650–1.PubMedCrossRef Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol. 2004;50(4):650–1.PubMedCrossRef
84.
go back to reference Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther. 2008;30(5):930–40.PubMedCrossRef Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther. 2008;30(5):930–40.PubMedCrossRef
85.
go back to reference Wang G, Zhuo N, Li J. Acute generalized exanthematous pustulosis induced by generic hydroxychloroquine. J of Cosmetic Dermatology. 2022;21(8):3608–10.PubMedCrossRef Wang G, Zhuo N, Li J. Acute generalized exanthematous pustulosis induced by generic hydroxychloroquine. J of Cosmetic Dermatology. 2022;21(8):3608–10.PubMedCrossRef
86.
go back to reference Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol. 2009;28(12):1449–52.PubMedCrossRef Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol. 2009;28(12):1449–52.PubMedCrossRef
87.
go back to reference Mercogliano C, Khan M, Lin C, Mohanty E, Zimmerman R. AGEP overlap induced by hydroxychloroquine: a case report and literature review. J Community Hosp Intern Med Perspect. 2018;8(6):360–2.PubMedPubMedCentralCrossRef Mercogliano C, Khan M, Lin C, Mohanty E, Zimmerman R. AGEP overlap induced by hydroxychloroquine: a case report and literature review. J Community Hosp Intern Med Perspect. 2018;8(6):360–2.PubMedPubMedCentralCrossRef
88.
go back to reference Coleman I, Ruiz G, Brahmbhatt S, Ackerman L. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. J Med Case Rep. 2020;14(1):210.PubMedPubMedCentralCrossRef Coleman I, Ruiz G, Brahmbhatt S, Ackerman L. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. J Med Case Rep. 2020;14(1):210.PubMedPubMedCentralCrossRef
90.
go back to reference Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000 Faculty Rev-612.PubMedPubMedCentralCrossRef Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000 Faculty Rev-612.PubMedPubMedCentralCrossRef
91.
go back to reference Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin Dermatol. 2020;38(6):607–12.PubMedCrossRef Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin Dermatol. 2020;38(6):607–12.PubMedCrossRef
92.
go back to reference Dodiuk-Gad RP, Olteanu C, Jeschke MG, Cartotto R, Fish J, Shear NH. Treatment of toxic epidermal necrolysis in North America. J Am Acad Dermatol. 2015;73(5):876-877.e2.PubMedCrossRef Dodiuk-Gad RP, Olteanu C, Jeschke MG, Cartotto R, Fish J, Shear NH. Treatment of toxic epidermal necrolysis in North America. J Am Acad Dermatol. 2015;73(5):876-877.e2.PubMedCrossRef
93.
go back to reference Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol. 2008;27(4):537–9.PubMedCrossRef Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol. 2008;27(4):537–9.PubMedCrossRef
94.
go back to reference Hama N, Abe R, Gibson A, Phillips EJ. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-1167.e5.PubMedPubMedCentralCrossRef Hama N, Abe R, Gibson A, Phillips EJ. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-1167.e5.PubMedPubMedCentralCrossRef
95.
go back to reference Randhawa A, Wylie G. A case of an acute cutaneous drug reaction with hydroxychloroquine. Scott Med J. 2018;63(3):91–4.PubMedCrossRef Randhawa A, Wylie G. A case of an acute cutaneous drug reaction with hydroxychloroquine. Scott Med J. 2018;63(3):91–4.PubMedCrossRef
96.
go back to reference Papazisis G, Siafis S, Cepatyte D, Giannis D, Stamoula E, Tzachanis D, et al. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. Eur Rev Med Pharmacol Sci. 2021;25(19):6003–12.PubMed Papazisis G, Siafis S, Cepatyte D, Giannis D, Stamoula E, Tzachanis D, et al. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. Eur Rev Med Pharmacol Sci. 2021;25(19):6003–12.PubMed
97.
go back to reference Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. Hydroxychloroquine safety: a meta-analysis of randomized controlled trials. Travel Med Infect Dis. 2020;36: 101812.PubMedPubMedCentralCrossRef Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. Hydroxychloroquine safety: a meta-analysis of randomized controlled trials. Travel Med Infect Dis. 2020;36: 101812.PubMedPubMedCentralCrossRef
98.
go back to reference Zhang S, Liu X, Cai L, Zhang J, Zhou C. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. Lupus. 2019;28(1):129–32.PubMedCrossRef Zhang S, Liu X, Cai L, Zhang J, Zhou C. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. Lupus. 2019;28(1):129–32.PubMedCrossRef
99.
go back to reference Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol. 2006;7(4):249–57.PubMedCrossRef Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol. 2006;7(4):249–57.PubMedCrossRef
100.
go back to reference Drew JF. Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic disease. Med J Aust. 1962;2(16):618–20.CrossRef Drew JF. Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic disease. Med J Aust. 1962;2(16):618–20.CrossRef
101.
go back to reference Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018;26(5):1141–9.PubMedCrossRef Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018;26(5):1141–9.PubMedCrossRef
102.
103.
go back to reference Biswas PS, Sen D, Majumdar R. Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. Gen Hosp Psychiatry. 2014;36(2):181–6.PubMedCrossRef Biswas PS, Sen D, Majumdar R. Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. Gen Hosp Psychiatry. 2014;36(2):181–6.PubMedCrossRef
104.
go back to reference Talarico F, Chakravarty S, Liu YS, Greenshaw AJ, Passos IC, Cao B. Systematic review of psychiatric adverse effects induced by chloroquine and hydroxychloroquine: case reports and population studies. Ann Pharmacother. 2023;57(4):463–79.PubMedCrossRef Talarico F, Chakravarty S, Liu YS, Greenshaw AJ, Passos IC, Cao B. Systematic review of psychiatric adverse effects induced by chloroquine and hydroxychloroquine: case reports and population studies. Ann Pharmacother. 2023;57(4):463–79.PubMedCrossRef
105.
go back to reference Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54(8):1185–9.PubMedCrossRef Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54(8):1185–9.PubMedCrossRef
106.
go back to reference Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends. 2020;14(2):139–43.PubMedCrossRef Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends. 2020;14(2):139–43.PubMedCrossRef
107.
go back to reference de Moraes Falcão LT, Terrabuio DRB, Diniz MA, da Silva Evangelista A, Souza FG, Cancado REL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open. 2020;4(3):371–7.CrossRef de Moraes Falcão LT, Terrabuio DRB, Diniz MA, da Silva Evangelista A, Souza FG, Cancado REL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open. 2020;4(3):371–7.CrossRef
108.
go back to reference Nagaraja BS, Ramesh KN, Dhar D, Mondal MS, Dey T, Saha S, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Oxf). 2020;42(3):493–503.PubMedCrossRef Nagaraja BS, Ramesh KN, Dhar D, Mondal MS, Dey T, Saha S, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Oxf). 2020;42(3):493–503.PubMedCrossRef
109.
go back to reference Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). 2021;60(7):3222–34.PubMedCrossRef Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). 2021;60(7):3222–34.PubMedCrossRef
110.
go back to reference Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020;34(7):1775–86.PubMedPubMedCentralCrossRef Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020;34(7):1775–86.PubMedPubMedCentralCrossRef
111.
go back to reference Giraud EL, Jessurun NT, van Hunsel FPAM, van Puijenbroek EP, van Tubergen A, Ten Klooster PM, et al. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opin Drug Saf. 2020;19(12):1617–24.PubMedCrossRef Giraud EL, Jessurun NT, van Hunsel FPAM, van Puijenbroek EP, van Tubergen A, Ten Klooster PM, et al. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opin Drug Saf. 2020;19(12):1617–24.PubMedCrossRef
112.
go back to reference Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric disorders and hydroxychloroquine for coronavirus disease 2019 (COVID-19): a VigiBase study. Drug Saf. 2020;43(12):1315–22.PubMedPubMedCentralCrossRef Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric disorders and hydroxychloroquine for coronavirus disease 2019 (COVID-19): a VigiBase study. Drug Saf. 2020;43(12):1315–22.PubMedPubMedCentralCrossRef
113.
go back to reference Awada G, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, Neyns B. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Melanoma Res. 2022;32(3):183–91.PubMedCrossRef Awada G, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, Neyns B. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Melanoma Res. 2022;32(3):183–91.PubMedCrossRef
114.
go back to reference Plesnicar B, Velikonja I, Plesnicar A, Vitorovic S. Two challenge and rechallenge episodes of chloroquine-induced psychotic mania in a patient with rheumatoid arthritis. Akt Rheumatol. 2013;38(03):177–9.CrossRef Plesnicar B, Velikonja I, Plesnicar A, Vitorovic S. Two challenge and rechallenge episodes of chloroquine-induced psychotic mania in a patient with rheumatoid arthritis. Akt Rheumatol. 2013;38(03):177–9.CrossRef
115.
go back to reference Kwak YT, Yang Y, Park SY. Chloroquine-associated psychosis mimicking very late-onset schizophrenia: case report. Geriatr Gerontol Int. 2015;15(8):1096–7.PubMedCrossRef Kwak YT, Yang Y, Park SY. Chloroquine-associated psychosis mimicking very late-onset schizophrenia: case report. Geriatr Gerontol Int. 2015;15(8):1096–7.PubMedCrossRef
117.
go back to reference Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78(1):100-106.e1.PubMedCrossRef Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78(1):100-106.e1.PubMedCrossRef
118.
go back to reference Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12(5 Pt 1):863–5.PubMedCrossRef Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12(5 Pt 1):863–5.PubMedCrossRef
119.
go back to reference Ferraro V, Mantoux F, Denis K, Lay-Macagno MA, Ortonne JP, Lacour JP. Hallucinations au cours d’un traitement par hydroxychloroquine. Ann Dermatol Venereol. 2004;131(5):471–3.PubMedCrossRef Ferraro V, Mantoux F, Denis K, Lay-Macagno MA, Ortonne JP, Lacour JP. Hallucinations au cours d’un traitement par hydroxychloroquine. Ann Dermatol Venereol. 2004;131(5):471–3.PubMedCrossRef
120.
go back to reference Ganjei Z, Bahmani K. A case report of hydroxychloroquine-induced auditory and visual hallucination. Int J Clin Pharmacol Ther. 2021;59(03):254–6.PubMedCrossRef Ganjei Z, Bahmani K. A case report of hydroxychloroquine-induced auditory and visual hallucination. Int J Clin Pharmacol Ther. 2021;59(03):254–6.PubMedCrossRef
121.
go back to reference Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284–90.PubMedCrossRef Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284–90.PubMedCrossRef
122.
go back to reference Petri M, Konig MF, Li J, Goldman DW. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(6):997–1004.PubMedPubMedCentralCrossRef Petri M, Konig MF, Li J, Goldman DW. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(6):997–1004.PubMedPubMedCentralCrossRef
123.
go back to reference Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018;103(6):1074–82.PubMedCrossRef Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018;103(6):1074–82.PubMedCrossRef
124.
go back to reference Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis & Rheumatol. 2020;72(3):448–53.CrossRef Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis & Rheumatol. 2020;72(3):448–53.CrossRef
125.
go back to reference Lenfant T, Salah S, Leroux G, Bousquet E, Le Guern V, Chasset F, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford). 2020;59(12):3807–16.PubMedCrossRef Lenfant T, Salah S, Leroux G, Bousquet E, Le Guern V, Chasset F, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford). 2020;59(12):3807–16.PubMedCrossRef
Metadata
Title
Safety of Hydroxychloroquine: What a Dermatologist Should Know
Authors
Luca Rapparini
Stephano Cedirian
Michelangelo La Placa
Bianca Maria Piraccini
Emanuel Raschi
Michela Starace
Publication date
03-02-2025
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-025-00919-x